X4製藥 XFOR 深 滬
等待開盤 11-04 09:30:00 美东时间
3.17
-0.180
-5.37%
華盛通- 最 高3.42
- 今 開3.37
- 成交量 63.11万股
- 最 低 3.135
- 昨 收 3.35
- 總市值 3.14亿
- 52周最高 4.83
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 2.43
- 委 比 -33.15%
- 總股本 9914.67万
- 歷史最高 717.90
- 量 比 0.74
- 振 幅 8.51%
- 歷史最低 1.35
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多X4 Pharmaceuticals Highlights Strategic Focus on Rare Hematology
X4 Pharmaceuticals ( ($XFOR) ) has issued an announcement. On October 29, 2026,...
10-29 22:22
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
X4 Pharmaceuticals highlights progress on mavorixafor for primary chronic neutropenia (PCN), with a U.S. market opportunity of 15,000 patients, expandable to 30,000. The 4WARD Phase 3 trial aims to complete enrollment by Q4 2026, and the 4STEPS Phase 2b trial will assess G-CSF dose reduction, starting in Q1 2027. Topline data from both trials are expected in Q1 2028. Mavorixafor, an oral CXCR4 antagonist, targets a serious, underdiagnosed disease...
10-29 20:30
X4 Pharmaceuticals secures up to $150M debt facility
X4 Pharmaceuticals (XFOR) said it entered into a senior secured term loan facility of up to $150M with K2 HealthVentures, replacing its previous loan agreement and providing the company with additiona...
10-08 19:33
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
BioCryst Pharmaceuticals announced the formation of a Scientific Advisory Board (SAB) comprising seven experts in rare disease research and drug development. The SAB will provide strategic guidance to enhance the company's R&D strategy, focusing on external innovation and pipeline expansion. The board includes leaders with extensive experience in rare disease drug discovery, translational science, and clinical development. BioCryst aims to levera...
10-05 11:00
X4 Pharmaceuticals shares are trading lower. The company announced the FDA’s agreement to reduce the 4WARD Phase 3 trial sample size. Enrollment is expected to finish by year-end 2026, with topline data in H1 2028.
X4 Pharmaceuticals shares are trading lower. The company announced the FDA’s agreement to reduce the 4WARD Phase 3 trial sample size. Enrollment is expected to finish by year-end 2026, with topline data in H1 2028.
09-08 22:28
X4 Pharmaceuticals gains FDA support for 4WARD trial
X4 Pharmaceuticals ( ($XFOR) ) has issued an update. X4 Pharmaceuticals, a Bost...
09-08 19:48
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
X4 Pharmaceuticals announced FDA agreement to reduce the sample size of its global 4WARD Phase 3 trial for chronic neutropenia from 176 to 126 participants, maintaining statistical power. The company expects trial enrollment completion by year-end 2026 and topline data in H1 2028. Mavorixafor aims to address chronic neutropenia, a rare blood disorder causing recurrent infections, by mobilizing neutrophils via CXCR4 inhibition.
09-08 11:00
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ:AIRS) fell sharply in pre-market trading following second-quarter results. AirSculpt Technologies posted second-quarter adjusted earnings of 1 cent per share, ...
08-10 20:02
X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
08-08 00:04
X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of $(3.47) per share from the same period last year. The company reported quarterly sales of $8.806 mill...
08-07 05:22
